Novel protein structures at scale

Replacing a 100 year old method

One Platform to conquer all.

Our universal technology platform enables generating synthetic proteins at the highest yields and purity. This platform allows creating novel protein-based drugs with entire novel mechanisms of action and manufacture them at scale.

We have a strong background on antimicrobials such as bacteriophages, lysins, and tailocins, but are gradually focusing on neoantigens and others multi-protein structures. Our strongest achievement was expressing bacteriophages in vitro completely independent of its original host:

We created Invitris to build partnerships. We help speed up drug discovery & development and will soon be able to support GMP-manufacturing as well. Reach out:

Also supported by